Jaume Barallat1, Gema Fernández-Rivas2,3, Bibiana Quirant-Sánchez4,5, Victoria González2,6,7, Maria Doladé1, Eva Martinez-Caceres4,5, Monica Piña8, Joan Matllo9, Oriol Estrada10, Ignacio Blanco11,12. 1. Servei d'Anàlisis Clínics i Bioquímica, Laboratori Clínic de la Metropolitana Nord, Gerència Territorial Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain. 2. Servei de Microbiologia, Laboratori Clínic de la Metropolitana Nord, Gerència Territorial Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain. 3. Departament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Barcelona, Spain. 4. Servei d'Immunologia, Laboratori Clínic de la Metropolitana Nord, Gerència Territorial Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain. 5. Departament de Biologia Celular, Fisiologia i Immunologia, Universitat Autònoma Barcelona, Barcelona, Spain. 6. Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Departament de Salut, Generalitat de Catalunya, Badalona, Spain. 7. CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 8. Unitat Bàsica de Prevenció, Direcció Atenció Primària, Gerencia Territorial Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain. 9. Unitat Bàsica de Prevenció, Hospital Germans Trias i Pujol, Gerencia Territorial Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain. 10. Direcció d'innovació i processos transversals, Gerencia Territorial Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain. 11. Servei de Genètica Clínica, Laboratori Clínic de la Metropolitana Nord, Gerència Territorial Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain. 12. Departament de Cirurgia, Universitat Autònoma Barcelona, Barcelona, Spain.
Abstract
BACKGROUND: The rapid spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) around the world has caused a global pandemic, infecting millions of individuals, with an unprecedented impact in health care systems worldwide. Healthcare workers are one of the risk groups that need to be well protected, due to their strategic role in patient management, presently and in prevention of healthcare needs for future outbreaks. Here, we present the results of the first SARS-CoV-2 seroprevalence study in the Northern Metropolitan Area of Barcelona, Spain. METHODS: IgG SARS-CoV-2 antibodies were analyzed in serum samples from 7563 healthcare workers of the Northern Metropolitan Area of Barcelona. Samples were collected after the first pandemic wave (from May 4th to May 22nd, 2020) and were analyzed by automated chemiluminescence assays. All samples were tested for IgG anti-S1/S2. Participant samples with negative or equivocal results but with analytical signals above the limit of detection and/or previously confirmed COVID-19 diagnosis were also tested for IgG anti-Nucleocapsid. RESULTS: A total of 779 of 7563 (10.3%) healthcare workers were positive for anti-SARS-CoV-2 IgG (specific for either S1/S2 or N antigens). No significant differences were observed between those working at primary care or at the reference hospital. Interestingly, among 341 participants with a confirmed COVID-19 diagnosis, 36 (10.55%) tested negative for SARS-CoV-2 IgG (both S1/S2 and recombinant N antigen). CONCLUSION: Seroprevalence of anti-SARS-CoV-2 IgG in the healthcare workers of the North Metropolitan Area of Barcelona was higher than in the general population in the same geographical area. Safety measures have to be stressed in order to protect these essential workers from future pandemic waves.
BACKGROUND: The rapid spread of n class="Species">Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) around the world has caused a global pandemic, infecting millions of individuals, with an unprecedented impact in health care systems worldwide. Healthcare workers are one of the risk groups that need to be well protected, due to their strategic role in patient management, presently and in prevention of healthcare needs for future outbreaks. Here, we present the results of the first SARS-CoV-2 seroprevalence study in the Northern Metropolitan Area of Barcelona, Spain. METHODS: IgG SARS-CoV-2 antibodies were analyzed in serum samples from 7563 healthcare workers of the Northern Metropolitan Area of Barcelona. Samples were collected after the first pandemic wave (from May 4th to May 22nd, 2020) and were analyzed by automated chemiluminescence assays. All samples were tested for IgG anti-S1/S2. Participant samples with negative or equivocal results but with analytical signals above the limit of detection and/or previously confirmed COVID-19 diagnosis were also tested for IgG anti-Nucleocapsid. RESULTS: A total of 779 of 7563 (10.3%) healthcare workers were positive for anti-SARS-CoV-2 IgG (specific for either S1/S2 or N antigens). No significant differences were observed between those working at primary care or at the reference hospital. Interestingly, among 341 participants with a confirmed COVID-19 diagnosis, 36 (10.55%) tested negative for SARS-CoV-2 IgG (both S1/S2 and recombinant N antigen). CONCLUSION: Seroprevalence of anti-SARS-CoV-2 IgG in the healthcare workers of the North Metropolitan Area of Barcelona was higher than in the general population in the same geographical area. Safety measures have to be stressed in order to protect these essential workers from future pandemic waves.
Authors: C Avellaneda Martínez; J C Santos Pastor; I M Marcos Sánchez; A Narros Giménez; M Gutiérrez de Antón; P Alonso Chacón Journal: Rev Esp Quimioter Date: 2022-01-17 Impact factor: 1.553
Authors: Steven He; Anthony Hecimovic; Vesna Matijasevic; Ha Thi Mai; Linda Heslop; Jann Foster; Kate E Alexander; Naru Pal; Evan Alexandrou; Patricia M Davidson; Steven A Frost Journal: J Clin Nurs Date: 2021-09-27 Impact factor: 4.423
Authors: Nicholas Brousseau; Laurianne Morin; Manale Ouakki; Patrice Savard; Caroline Quach; Yves Longtin; Matthew P Cheng; Alex Carignan; Simon F Dufresne; Jean-Michel Leduc; Christian Lavallée; Nicolas Gauthier; Julie Bestman-Smith; Maria-Jesus Arrieta; Magued Ishak; Simon Lévesque; Philippe Martin; Gaston De Serres Journal: CMAJ Date: 2022-03-07 Impact factor: 16.859
Authors: Eva Escribano Ceruelo; Marco Antonio Espinel Ruíz; Marta Ortega López-Peláez; Bárbara Fernández Garoz; Julia Asensio Antón; Raquel Jiménez García Journal: Enferm Infecc Microbiol Clin (Engl Ed) Date: 2021-01-19
Authors: Martin Lier; Stefan Nessler; Christine Stadelmann; Meike Pressler; Leif Saager; Onnen Moerer; Markus Roessler; Konrad Meissner; Martin S Winkler Journal: Scand J Trauma Resusc Emerg Med Date: 2021-10-30 Impact factor: 2.953
Authors: Vera S Kichatova; Fedor A Asadi Mobarkhan; Ilya A Potemkin; Sergey P Zlobin; Oksana M Perfilieva; Vladimir T Valuev-Elliston; Alexander V Ivanov; Sergey A Solonin; Mikhail A Godkov; Maria G Belikova; Mikhail I Mikhailov; Karen K Kyuregyan Journal: Microorganisms Date: 2022-02-12